Ovarian Neoplasms Clinical Trials

44 recruitingLast updated: June 17, 2026

There are 44 actively recruiting ovarian neoplasms clinical trials across 34 countries. Studies span Phase 1, Phase 2, Phase 3, Not Applicable. Top locations include Boston, Massachusetts, United States, New York, New York, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Ovarian Neoplasms Trials at a Glance

44 actively recruiting trials for ovarian neoplasms are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 1 with 12 trials, with the heaviest enrollment activity in Boston, New York, and Houston. Lead sponsors running ovarian neoplasms studies include Eli Lilly and Company, Cancer Research UK, and A2 Biotherapeutics Inc..

Browse ovarian neoplasms trials by phase

Treatments under study

About Ovarian Neoplasms Clinical Trials

Looking for clinical trials for Ovarian Neoplasms? There are currently 43 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ovarian Neoplasms trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ovarian Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 44 trials

Recruiting
Phase 1

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Ovarian NeoplasmsStomach NeoplasmsLung Neoplasms+5 more
National Cancer Institute (NCI)100 enrolled1 locationNCT06885697
Recruiting
Phase 3

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,630 enrolled261 locationsNCT07213804
Recruiting
Phase 3

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Ovarian CancerOvarian Neoplasms
Merck Sharp & Dohme LLC900 enrolled99 locationsNCT07318558
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Colorectal, CancerOvarian CancerLung Cancer+17 more
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting
Phase 1

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more
Eli Lilly and Company241 enrolled30 locationsNCT07213791
Recruiting
Phase 1Phase 2

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Cervical CancerUrothelial CarcinomaMelanoma+8 more
Bristol-Myers Squibb1,109 enrolled47 locationsNCT04895709
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled159 locationsNCT04389632
Recruiting
Phase 1Phase 2

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckOvarian Neoplasms+8 more
Cancer Research UK167 enrolled4 locationsNCT06380816
Recruiting
Phase 2

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

Ovarian NeoplasmsUterine Cervical NeoplasmsEndometrial Neoplasms+3 more
Yonsei University198 enrolled27 locationsNCT06023862
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1Phase 2

Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites

AscitesOvarian Neoplasms Malignant
Cancer Institute and Hospital, Chinese Academy of Medical Sciences29 enrolled1 locationNCT07435701
Recruiting
Not Applicable

Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions

Ovarian CarcinomaOvarian NeoplasmsFemale Reproductive System Adnexal Neoplasm+3 more
Mayo Clinic40 enrolled1 locationNCT07280312
Recruiting
Phase 1

A Study of DM002 in Patients With Advanced Solid Tumors

Ovarian NeoplasmsColorectal NeoplasmsEndometrial Neoplasms+2 more
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.160 enrolled5 locationsNCT06751329
Recruiting
Phase 1

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Carcinoma, Non-Small Cell LungOvarian NeoplasmsUterine Cervical Neoplasms+4 more
Eli Lilly and Company495 enrolled23 locationsNCT06400472
Recruiting
Phase 3

Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)

Ovarian Neoplasms
Instituto de Investigacion Sanitaria La Fe200 enrolled1 locationNCT06963268
Recruiting
Not Applicable

OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study

Ovarian CancerOvarian CarcinomaOvarian Neoplasms+2 more
Gynaecologisch Oncologisch Centrum Zuid90 enrolled1 locationNCT06611072
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

Ovarian NeoplasmsColorectal NeoplasmsUrinary Bladder Neoplasm+8 more
Cancer Research UK30 enrolled27 locationsNCT05786716
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

MelanomaCarcinoma, Non-Small Cell LungOvarian Neoplasms+9 more
Cancer Research UK30 enrolled16 locationsNCT05768178
Recruiting
Not Applicable

Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer

Ovarian CancerOvarian CarcinomaOvarian Neoplasms
Dana-Farber Cancer Institute112 enrolled1 locationNCT06543537